A slowing economy and surging homegrown brands are rewriting the balance of power in the world's most important luxury market ...

Entrada Therapeutics reported a 3Q25 GAAP EPS loss of –$1.06 and revenue of $1.6 million, reflecting declining collaboration ...

Available funding totaling EUR 20 million dedicated to developing novel solid tumor treatments addressing a high unmet medical needSpringboard Health Angels, Pluton Asset Holding AG, Sintra Limited, ...